Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Times Guadeloupe.
Press releases published on September 4, 2025
Walden Biosciences Announces Key Initiatives to Advance Clinical Pipeline and Support Phase 2 Program for WAL0921 in Rare Kidney Diseases
GlobeNewswire
·
September 4, 2025
Engages Former FDA Director of Division of Cardiology and Nephrology, Norman Stockbridge, M.D., Ph.D., to Advise on Walden’s Clinical Pipeline in Rare Kidney Diseases Utilizes Rare Kidney Disease Patient Advocacy Group to Broaden Awareness and Outreach …
Cancer Focus Fund Appoints Distinguished Industry Experts David R. Epstein and Michael Margolis as Advisors to Its Investment Committee
GlobeNewswire
·
September 4, 2025
—Epstein and Margolis Bring Decades of Business Expertise and Industry Leadership to Cancer Focus Fund as It Prepares for Its Next Round of Investments— HOUSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cancer Focus Fund, LP, a unique investment fund established …
BPGbio Announces Completion of Enrollment for Phase 2b Trial of BPM31510 for Glioblastoma (GBM)
GlobeNewswire
·
September 4, 2025
Topline Phase 2b Clinical Data Expected in 1H 2026 Trial-in-Progress Presentations Scheduled for ESMO and SNO in Fall 2025 BPM31510 has Received Orphan Drug Designation from the U.S. FDA for the Treatment of GBM BOSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- …
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
NEW HAVEN, Conn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO …
Algernon Pharmaceuticals Announces Name Change to Algernon Health
GlobeNewswire
·
September 4, 2025
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it is changing its name to Algernon Health …
Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model
GlobeNewswire
·
September 4, 2025
Skye shares new preclinical DIO data at virtual KOL event Nimacimab + tirzepatide demonstrates over 40% weight loss in multiple preclinical DIO studies Nimacimab demonstrates durable post-treatment weight loss compared to tirzepatide Nimacimab reduced …
Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10
GlobeNewswire
·
September 4, 2025
CALGARY, Alberta, Sept. 04, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …
Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia
GlobeNewswire
·
September 4, 2025
PDUFA goal date extended by three months from September 7, 2025, to December 7, 2025 CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering …
Sol-Gel Announces Health Canada Approval of EPSOLAY®
GlobeNewswire
·
September 4, 2025
NESS ZIONA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for …
Merakris Therapeutics Enrolls 30th Subject in Expanded Access Program of MTX-001; Highlights Clinical Progress at SAWC Fall 2025
GlobeNewswire
·
September 4, 2025
RESEARCH TRIANGLE PARK, N.C, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics, a regenerative medicine company developing biologically derived therapeutics, announced the enrollment of the 30th subject in its Expanded Access Program (EAP) of MTX- …
Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced …
Lygos Clinic Launches VIP All-Inclusive Dental Tourism Packages for International Patients
GlobeNewswire
·
September 4, 2025
ISTANBUL, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lygos Clinic, a leading dental center in Istanbul, has officially launched its new VIP all-inclusive dental tourism packages, designed to meet the rising global demand for premium, affordable cosmetic dentistry. …
Onco3R Therapeutics Announces Approval of First Clinical Trial Application for Novel SIK3 inhibitor O3R-5671 in Autoimmune Diseases
GlobeNewswire
·
September 4, 2025
O3R-5671 is designed to overcome the limitations of first-generation SIK inhibitors, providing a potential new oral treatment option for multiple autoimmune diseases Clinical Trial Application approval marks Onco3R’s transition into a clinical-stage …
PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025
GlobeNewswire
·
September 4, 2025
PARIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology announces that its CSO, Thierry Bordet Ph.D., will present …
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
GlobeNewswire
·
September 4, 2025
MINNEAPOLIS and BRISBANE, Australia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting- …
Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed
GlobeNewswire
·
September 4, 2025
Company expects to fully repay existing financial debts in 2026 NCX 470 NDA submissions in U.S. (H1 2026) and subsequently in China Milestones payable on U.S. NDA submission and on approval Glaukos extends NCX 1728 research agreement Future strategic …
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
GlobeNewswire
·
September 4, 2025
Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically …
Communiqué de presse : L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique
GlobeNewswire
·
September 4, 2025
L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique L’amlitelimab, administré toutes les quatre semaines ou …
ProductLife Group Expands to Deliver Localized Expertise & Enhanced Client Support in Japan
GlobeNewswire
·
September 4, 2025
PARIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- ProductLife Group (PLG) is proud to announce the opening of its newest office in Japan, reinforcing its commitment to meeting evolving client needs and market demands. This expansion enhances capacity, strengthens …
JUST ON SLEEP Officially Launches on Shopee Singapore, Redefining Sleep Safety and Wellness
GlobeNewswire
·
September 4, 2025
SINGAPORE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- JUST ON SLEEP, a smart contactless sleep monitoring device developed by Sewon Intelligence, has recently launched in Singapore via Shopee, making advanced sleep wellness and safety solutions more accessible to …